{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T11:46:58Z","timestamp":1782474418663,"version":"3.54.5"},"reference-count":56,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2026,4,2]],"date-time":"2026-04-02T00:00:00Z","timestamp":1775088000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,4,2]],"date-time":"2026-04-02T00:00:00Z","timestamp":1775088000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Hematol"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1007\/s12185-026-04195-1","type":"journal-article","created":{"date-parts":[[2026,4,2]],"date-time":"2026-04-02T15:59:35Z","timestamp":1775145575000},"page":"824-836","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Anti-CD38-based quadruplet versus triplet induction regimens in transplant-ineligible newly diagnosed multiple myeloma: a systematic review and meta-analysis"],"prefix":"10.1007","volume":"123","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1812-0639","authenticated-orcid":false,"given":"Grace","family":"Lau","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Madhu Bhargavi","family":"Chandra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henri","family":"Fero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fahad","family":"Alabbas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,2]]},"reference":[{"key":"4195_CR1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2024.113921","volume":"201","author":"N Abildgaard","year":"2024","unstructured":"Abildgaard N, Anttila P, Waage A, Rubin KH, \u00d8rstavik S, Bent-Ennakhil N, et al. Real-world treatment patterns and outcomes for patients with multiple myeloma in Denmark, Finland and Sweden: an analysis using linked Nordic registries. Eur J Cancer. 2024;201:113921.","journal-title":"Eur J Cancer"},{"issue":"9","key":"4195_CR2","doi-asserted-by":"publisher","first-page":"e670","DOI":"10.1016\/S2352-3026(22)00165-X","volume":"9","author":"J Huang","year":"2022","unstructured":"Huang J, Chan SC, Lok V, Zhang L, Lucero-Prisno DE, Xu W, et al. The epidemiological landscape of multiple myeloma: a global cancer registry estimate of disease burden, risk factors, and temporal trends. Lancet Haematol. 2022;9(9):e670\u20137.","journal-title":"Lancet Haematol."},{"issue":"10192","key":"4195_CR3","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/S0140-6736(19)31240-1","volume":"394","author":"P Moreau","year":"2019","unstructured":"Moreau P, Attal M, Hulin C, Arnulf B, Belhadj K, Benboubker L, et al. Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 study. The Lancet. 2019;394(10192):29\u201338.","journal-title":"The Lancet"},{"issue":"8","key":"4195_CR4","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.1016\/S1470-2045(24)00282-1","volume":"25","author":"P Moreau","year":"2024","unstructured":"Moreau P, Hulin C, Perrot A, Arnulf B, Belhadj K, Benboubker L, et al. Bortezomib, thalidomide, and dexamethasone with or without daratumumab and followed by daratumumab maintenance or observation in transplant-eligible newly diagnosed multiple myeloma: long-term follow-up of the CASSIOPEIA randomised controlled phase 3 trial. Lancet Oncol. 2024;25(8):1003\u201314.","journal-title":"Lancet Oncol"},{"issue":"8","key":"4195_CR5","doi-asserted-by":"publisher","first-page":"936","DOI":"10.1182\/blood.2020005288","volume":"136","author":"PM Voorhees","year":"2020","unstructured":"Voorhees PM, Kaufman JL, Laubach J, Sborov DW, Reeves B, Rodriguez C, et al. Daratumumab, lenalidomide, bortezomib, and dexamethasone for transplant-eligible newly diagnosed multiple myeloma: the GRIFFIN trial. Blood. 2020;136(8):936\u201345.","journal-title":"Blood"},{"issue":"10","key":"4195_CR6","doi-asserted-by":"publisher","first-page":"e825","DOI":"10.1016\/S2352-3026(23)00217-X","volume":"10","author":"PM Voorhees","year":"2023","unstructured":"Voorhees PM, Sborov DW, Laubach J, Kaufman JL, Reeves B, Rodriguez C, et al. Addition of daratumumab to lenalidomide, bortezomib, and dexamethasone for transplantation-eligible patients with newly diagnosed multiple myeloma (GRIFFIN): final analysis of an open-label, randomised, phase 2 trial. Lancet Haematol. 2023;10(10):e825\u201337.","journal-title":"Lancet Haematol"},{"issue":"4","key":"4195_CR7","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1056\/NEJMoa2312054","volume":"390","author":"P Sonneveld","year":"2024","unstructured":"Sonneveld P, Dimopoulos MA, Boccadoro M, Quach H, Ho PJ, Beksac M, et al. Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma. N Engl J Med. 2024;390(4):301\u201313.","journal-title":"N Engl J Med"},{"issue":"11","key":"4195_CR8","doi-asserted-by":"publisher","first-page":"1279","DOI":"10.1200\/JCO-24-02266","volume":"43","author":"EK Mai","year":"2025","unstructured":"Mai EK, Bertsch U, Pozek E, Fenk R, Besemer B, Hanoun C, et al. Isatuximab, Lenalidomide, Bortezomib, and Dexamethasone Induction Therapy for Transplant-Eligible Newly Diagnosed Multiple Myeloma: Final Part 1 Analysis of the GMMG-HD7 Trial. J Clin Oncol. 2025;43(11):1279\u201388.","journal-title":"J Clin Oncol"},{"issue":"3","key":"4195_CR9","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1182\/blood.2022017635","volume":"143","author":"T Facon","year":"2024","unstructured":"Facon T, Leleu X, Manier S. How I treat multiple myeloma in geriatric patients. Blood. 2024;143(3):224\u201332.","journal-title":"Blood"},{"issue":"1","key":"4195_CR10","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-020-07503-y","volume":"20","author":"R Fonseca","year":"2020","unstructured":"Fonseca R, Usmani SZ, Mehra M, Slavcev M, He J, Cote S, et al. Frontline treatment patterns and attrition rates by subsequent lines of therapy in patients with newly diagnosed multiple myeloma. BMC Cancer. 2020;20(1):1087.","journal-title":"BMC Cancer"},{"issue":"14","key":"4195_CR11","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2023.979111","volume":"12","author":"W Tang","year":"2023","unstructured":"Tang W, Yang J, Li Y, Zhang L, Li H, Wang J, et al. Treatment attrition rates and relevant risk factors in multiple myeloma: A real-world study in China. Front Pharmacol. 2023;12(14):979111.","journal-title":"Front Pharmacol"},{"issue":"1","key":"4195_CR12","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1038\/s41408-025-01311-y","volume":"15","author":"LG Rodr\u00edguez-Lobato","year":"2025","unstructured":"Rodr\u00edguez-Lobato LG, De Daniel A, Pereira A, Fern\u00e1ndez De Larrea C, Tovar N, Cibeira MT, et al. Attrition rates and treatment outcomes in multiple myeloma: real-world data over a 40-year period. Blood Cancer J. 2025;15(1):103.","journal-title":"Blood Cancer J"},{"issue":"8","key":"4195_CR13","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1016\/j.clml.2025.03.004","volume":"25","author":"A Perrot","year":"2025","unstructured":"Perrot A, Raguideau F, Denis H, Prodel M, Javelot M, Pierres M, et al. Survival, Years of Life Lost and Attrition Rates in Multiple Myeloma Patients in France. Clin Lymphoma Myeloma Leuk. 2025;25(8):606-614.e1.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"4195_CR14","doi-asserted-by":"crossref","unstructured":"Mohyuddin GR, Koehn K, Abdallah AO, Goodman AM, Prasad V. Reporting of Postprotocol Therapies and Attrition in Multiple Myeloma Randomized Clinical Trials: A Systematic Review. JAMA Netw Open [Internet]. 2021;4 (4). Available from: https:\/\/www-embase-com-443.cams.zssgdsb-85176920tsgjnz.com\/search\/results?subaction=viewrecord&id=L634902233&from=export.","DOI":"10.1001\/jamanetworkopen.2021.8084"},{"issue":"10","key":"4195_CR15","doi-asserted-by":"publisher","first-page":"906","DOI":"10.1056\/NEJMoa1402551","volume":"371","author":"L Benboubker","year":"2014","unstructured":"Benboubker L, Dimopoulos MA, Dispenzieri A, Catalano J, Belch AR, Cavo M, et al. Lenalidomide and Dexamethasone in Transplant-Ineligible Patients with Myeloma. N Engl J Med. 2014;371(10):906\u201317.","journal-title":"N Engl J Med"},{"issue":"10068","key":"4195_CR16","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1016\/S0140-6736(16)31594-X","volume":"389","author":"BGM Durie","year":"2017","unstructured":"Durie BGM, Hoering A, Abidi MH, Rajkumar SV, Epstein J, Kahanic SP, et al. Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem-cell transplant (SWOG S0777): a randomised, open-label, phase 3 trial. The Lancet. 2017;389(10068):519\u201327.","journal-title":"The Lancet"},{"issue":"5","key":"4195_CR17","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1038\/s41408-020-0311-8","volume":"10","author":"BGM Durie","year":"2020","unstructured":"Durie BGM, Hoering A, Sexton R, Abidi MH, Epstein J, Rajkumar SV, et al. Longer term follow-up of the randomized phase III trial SWOG S0777: bortezomib, lenalidomide and dexamethasone vs. lenalidomide and dexamethasone in patients (Pts) with previously untreated multiple myeloma without an intent for immediate autologous stem cell transplant (ASCT). Blood Cancer J. 2020;10(5):53.","journal-title":"Blood Cancer J"},{"issue":"22","key":"4195_CR18","doi-asserted-by":"publisher","first-page":"2104","DOI":"10.1056\/NEJMoa1817249","volume":"380","author":"T Facon","year":"2019","unstructured":"Facon T, Kumar S, Plesner T, Orlowski RZ, Moreau P, Bahlis N, et al. Daratumumab plus Lenalidomide and Dexamethasone for Untreated Myeloma. N Engl J Med. 2019;380(22):2104\u201315.","journal-title":"N Engl J Med"},{"issue":"4","key":"4195_CR19","doi-asserted-by":"publisher","first-page":"942","DOI":"10.1038\/s41375-024-02505-2","volume":"39","author":"T Facon","year":"2025","unstructured":"Facon T, Moreau P, Weisel K, Goldschmidt H, Usmani SZ, Chari A, et al. Daratumumab\/lenalidomide\/dexamethasone in transplant-ineligible newly diagnosed myeloma: MAIA long-term outcomes: Multiple Myeloma. Gammopathies Leukemia. 2025;39(4):942\u201350.","journal-title":"Gammopathies Leukemia"},{"issue":"6","key":"4195_CR20","doi-asserted-by":"publisher","first-page":"980","DOI":"10.3324\/haematol.2012.075051","volume":"98","author":"S Bringhen","year":"2013","unstructured":"Bringhen S, Mateos MV, Zweegman S, Larocca A, Falcone AP, Oriol A, et al. Age and organ damage correlate with poor survival in myeloma patients: meta-analysis of 1435 individual patient data from 4 randomized trials. Haematologica. 2013;98(6):980\u20137.","journal-title":"Haematologica"},{"key":"4195_CR21","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71","volume":"29","author":"MJ Page","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;29:n71.","journal-title":"BMJ"},{"issue":"8","key":"4195_CR22","doi-asserted-by":"publisher","first-page":"e328","DOI":"10.1016\/S1470-2045(16)30206-6","volume":"17","author":"S Kumar","year":"2016","unstructured":"Kumar S, Paiva B, Anderson KC, Durie B, Landgren O, Moreau P, et al. International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. Lancet Oncol. 2016;17(8):e328\u201346.","journal-title":"Lancet Oncol"},{"issue":"1","key":"4195_CR23","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1038\/s41375-019-0539-0","volume":"34","author":"T Facon","year":"2020","unstructured":"Facon T, Dimopoulos MA, Meuleman N, Belch A, Mohty M, Chen WM, et al. A simplified frailty scale predicts outcomes in transplant-ineligible patients with newly diagnosed multiple myeloma treated in the FIRST (MM-020) trial. Leukemia. 2020;34(1):224\u201333.","journal-title":"Leukemia"},{"key":"4195_CR24","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.l4898","volume":"28","author":"JAC Sterne","year":"2019","unstructured":"Sterne JAC, Savovi\u0107 J, Page MJ, Elbers RG, Blencowe NS, Boutron I, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019;28:l4898.","journal-title":"BMJ"},{"issue":"6","key":"4195_CR25","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1056\/NEJMoa1714678","volume":"378","author":"MV Mateos","year":"2018","unstructured":"Mateos MV, Dimopoulos MA, Cavo M, Suzuki K, Jakubowiak A, Knop S, et al. Daratumumab plus bortezomib, melphalan, and prednisone for untreated myeloma. N Engl J Med. 2018;378(6):518\u201328.","journal-title":"N Engl J Med"},{"issue":"5","key":"4195_CR26","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1016\/S1470-2045(25)00018-X","volume":"26","author":"MV Mateos","year":"2025","unstructured":"Mateos MV, San-Miguel J, Cavo M, Suzuki K, Jakubowiak A, Knop S, et al. Bortezomib, Melphalan, and Prednisone with or without Daratumumab in transplant-ineligible patients with newly diagnosed multiple myeloma (ALCYONE): final analysis of an open-label, randomised, multicentre, phase 3 trial. Lancet Oncol. 2025;26(5):596\u2013608.","journal-title":"Lancet Oncol"},{"issue":"6","key":"4195_CR27","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1016\/j.clml.2023.02.009","volume":"23","author":"W Fu","year":"2023","unstructured":"Fu W, Bang SM, Huang H, Kim K, Li W, An G, et al. Bortezomib, Melphalan, and Prednisone with or without Daratumumab in transplant-ineligible Asian patients with newly diagnosed multiple myeloma: The Phase 3 OCTANS study. Clin Lymphoma Myeloma Leuk. 2023;23(6):446-455.e4.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"1","key":"4195_CR28","first-page":"515","volume":"104","author":"W Fu","year":"2025","unstructured":"Fu W, Bang SM, Huang H, Kim K, Li W, An G, et al. Daratumumab, Bortezomib, Melphalan, and Prednisone versus Bortezomib, Melphalan, and Prednisone alone in transplant-ineligible Asian patients with newly diagnosed multiple myeloma: final analysis of the phase 3 OCTANS study. Ann Hematol. 2025;104(1):515\u201325.","journal-title":"Ann Hematol"},{"issue":"14","key":"4195_CR29","doi-asserted-by":"publisher","first-page":"3721","DOI":"10.1182\/bloodadvances.2023012539","volume":"8","author":"P Mollee","year":"2024","unstructured":"Mollee P, Reynolds J, Janowski W, Quach H, Campbell P, Gibbs S, et al. Daratumumab, Cyclophosphamide, Bortezomib, and Dexamethasone for transplant-ineligible myeloma: AMaRC 03-16. Blood Adv. 2024;8(14):3721\u201330.","journal-title":"Blood Adv"},{"issue":"17","key":"4195_CR30","doi-asserted-by":"publisher","first-page":"1597","DOI":"10.1056\/NEJMoa2400712","volume":"391","author":"T Facon","year":"2024","unstructured":"Facon T, Dimopoulos MA, Leleu XP, Beksac M, Pour L, H\u00e1jek R, et al. Isatuximab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma. N Engl J Med. 2024;391(17):1597\u2013609.","journal-title":"N Engl J Med"},{"issue":"4","key":"4195_CR31","doi-asserted-by":"publisher","first-page":"1195","DOI":"10.1038\/s41591-024-03485-7","volume":"31","author":"SZ Usmani","year":"2025","unstructured":"Usmani SZ, Facon T, Hungria V, Bahlis NJ, Venner CP, Braunstein M, et al. Daratumumab plus bortezomib, lenalidomide and dexamethasone for transplant-ineligible or transplant-deferred newly diagnosed multiple myeloma: the randomized phase 3 CEPHEUS trial. Nat Med. 2025;31(4):1195\u2013202.","journal-title":"Nat Med"},{"issue":"16_suppl","key":"4195_CR32","doi-asserted-by":"publisher","first-page":"7516","DOI":"10.1200\/JCO.2025.43.16_suppl.7516","volume":"43","author":"T Facon","year":"2025","unstructured":"Facon T, Zweegman S, Hungria V, Bahlis NJ, Venner CP, Braunstein MJ, et al. Daratumumab plus bortezomib, lenalidomide, and dexamethasone (DVRd) in patients with newly diagnosed multiple myeloma (NDMM): Subgroup analysis of transplant-ineligible (TIE) patients in the phase 3 CEPHEUS study. J Clin Oncol. 2025;43(16_suppl):7516.","journal-title":"J Clin Oncol"},{"issue":"8","key":"4195_CR33","doi-asserted-by":"publisher","first-page":"e588","DOI":"10.1016\/S2352-3026(25)00143-7","volume":"12","author":"MV Mateos","year":"2025","unstructured":"Mateos MV, Paiva B, Cedena MT, Puig N, Sureda-Balari AM, De La Calle VG, et al. Induction therapy with bortezomib, melphalan, and prednisone followed by lenalidomide and dexamethasone versus carfilzomib, lenalidomide, and dexamethasone with or without daratumumab in older, fit patients with newly diagnosed multiple myeloma (GEM-2017FIT): a phase 3, open-label, multicentre, randomised clinical trial. Lancet Haematol. 2025;12(8):e588\u201398.","journal-title":"Lancet Haematol"},{"issue":"5","key":"4195_CR34","doi-asserted-by":"publisher","first-page":"1976","DOI":"10.1007\/s12325-022-02083-8","volume":"39","author":"T Facon","year":"2022","unstructured":"Facon T, San-Miguel J, Dimopoulos MA, Mateos MV, Cavo M, van Beekhuizen S, et al. Treatment regimens for transplant-ineligible patients with newly diagnosed multiple myeloma: A systematic literature review and network meta-analysis. Adv Ther. 2022;39(5):1976\u201392.","journal-title":"Adv Ther"},{"key":"4195_CR35","unstructured":"Visram A. Temporal Trends in Infectious Risk Among Multiple Myeloma Patients Treated with Daratumumab: A Meta-Analysis."},{"issue":"2","key":"4195_CR36","doi-asserted-by":"publisher","first-page":"e143","DOI":"10.1016\/S2352-3026(21)00283-0","volume":"9","author":"NS Raje","year":"2022","unstructured":"Raje NS, Anaissie E, Kumar SK, Lonial S, Martin T, Gertz MA, et al. Consensus guidelines and recommendations for infection prevention in multiple myeloma: a report from the International Myeloma Working Group. Lancet Haematol. 2022;9(2):e143\u201361.","journal-title":"Lancet Haematol"},{"issue":"12","key":"4195_CR37","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1016\/j.clml.2021.07.013","volume":"21","author":"LL George","year":"2021","unstructured":"George LL, Malik MN, Miller EJ, Hicks K, Khanam R, Saterehaseman A, et al. Special considerations for supportive care and management of complications in elderly patients with multiple myeloma. Clin Lymphoma Myeloma Leuk. 2021;21(12):812\u201322.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"4195_CR38","doi-asserted-by":"publisher","DOI":"10.1016\/j.blre.2025.101287","volume":"72","author":"A Kannan","year":"2025","unstructured":"Kannan A, Jeffrey K, Misbah S, Ramasamy K. Practical guidance on the prevention and management of infection in multiple myeloma patients: A case-based approach. Blood Rev. 2025;72:101287.","journal-title":"Blood Rev"},{"issue":"8","key":"4195_CR39","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1016\/j.clml.2019.04.014","volume":"19","author":"AS Salazar","year":"2019","unstructured":"Salazar AS, Recinos LM, Mian HS, Stoll C, Simon LE, Sekhon S, et al. Geriatric assessment and frailty scores predict mortality in myeloma: systematic review and meta-analysis. Clin Lymphoma Myeloma Leuk. 2019;19(8):488-96.e6.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"8","key":"4195_CR40","doi-asserted-by":"publisher","DOI":"10.1016\/j.jgo.2024.102051","volume":"15","author":"A Gahagan","year":"2024","unstructured":"Gahagan A, Maheshwari S, Rangarajan S, Ubersax C, Tucker A, Harmon C, et al. Evaluating concordance between International Myeloma Working Group (IMWG) frailty score and simplified frailty scale among older adults with multiple myeloma. J Geriatr Oncol. 2024;15(8):102051.","journal-title":"J Geriatr Oncol"},{"issue":"13","key":"4195_CR41","doi-asserted-by":"publisher","first-page":"2068","DOI":"10.1182\/blood-2014-12-615187","volume":"125","author":"A Palumbo","year":"2015","unstructured":"Palumbo A, Bringhen S, Mateos MV, Larocca A, Facon T, Kumar SK, et al. Geriatric assessment predicts survival and toxicities in elderly myeloma patients: an International Myeloma Working Group report. Blood. 2015;125(13):2068\u201374.","journal-title":"Blood"},{"issue":"5","key":"4195_CR42","doi-asserted-by":"publisher","first-page":"910","DOI":"10.3324\/haematol.2016.162693","volume":"102","author":"M Engelhardt","year":"2017","unstructured":"Engelhardt M, Domm AS, Dold SM, Ihorst G, Reinhardt H, Zober A, et al. A concise revised Myeloma Comorbidity Index as a valid prognostic instrument in a large cohort of 801 multiple myeloma patients. Haematologica. 2017;102(5):910\u201321.","journal-title":"Haematologica"},{"issue":"11","key":"4195_CR43","doi-asserted-by":"publisher","first-page":"1129","DOI":"10.1002\/ajh.24532","volume":"91","author":"P Milani","year":"2016","unstructured":"Milani P, Vincent Rajkumar S, Merlini G, Kumar S, Gertz MA, Palladini G, et al. N-terminal fragment of the type-B natriuretic peptide (NT-proBNP) contributes to a simple new frailty score in patients with newly diagnosed multiple myeloma. Am J Hematol. 2016;91(11):1129\u201334.","journal-title":"Am J Hematol"},{"issue":"3","key":"4195_CR44","doi-asserted-by":"publisher","first-page":"e154","DOI":"10.1016\/S2352-3026(18)30220-5","volume":"6","author":"G Cook","year":"2019","unstructured":"Cook G, Royle KL, Pawlyn C, Hockaday A, Shah V, Kaiser MF, et al. A clinical prediction model for outcome and therapy delivery in transplant-ineligible patients with myeloma (UK Myeloma Research Alliance Risk Profile): a development and validation study. Lancet Haematol. 2019;6(3):e154\u201366.","journal-title":"Lancet Haematol"},{"issue":"7","key":"4195_CR45","doi-asserted-by":"publisher","first-page":"1769","DOI":"10.1007\/s00277-021-04529-5","volume":"100","author":"MJ Cejalvo","year":"2021","unstructured":"Cejalvo MJ, Bustamante G, Gonz\u00e1lez E, V\u00e1zquez-\u00c1lvarez J, Garc\u00eda R, Ram\u00edrez-Payer \u00c1, et al. Treatment patterns and outcomes in real-world transplant-ineligible patients newly diagnosed with multiple myeloma. Ann Hematol. 2021;100(7):1769\u201378.","journal-title":"Ann Hematol"},{"issue":"Supplement 1","key":"4195_CR46","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1182\/blood-2024-209653","volume":"144","author":"G Cook","year":"2024","unstructured":"Cook G, Pawlyn C, Royle KL, Senior ER, Everritt D, Bird J, et al. IMWG frailty score-adjusted therapy delivery reduces the early mortality risk in newly diagnosed tne multiple myeloma: results of the UK myeloma research alliance (UK-MRA) Myeloma XIV Fitness Trial. Blood. 2024;144(Supplement 1):673.","journal-title":"Blood"},{"issue":"22","key":"4195_CR47","doi-asserted-by":"publisher","first-page":"3027","DOI":"10.1182\/blood.2020009507","volume":"137","author":"A Larocca","year":"2021","unstructured":"Larocca A, Bonello F, Gaidano G, D\u2019Agostino M, Offidani M, Cascavilla N, et al. Dose\/schedule-adjusted Rd-R vs continuous Rd for elderly, intermediate-fit patients with newly diagnosed multiple myeloma. Blood. 2021;137(22):3027\u201336.","journal-title":"Blood"},{"key":"4195_CR48","doi-asserted-by":"publisher","first-page":"1369","DOI":"10.1182\/blood-2022-159933","volume":"140","author":"S Manier","year":"2022","unstructured":"Manier S, Corre J, Hulin C, Laribi K, Araujo C, Pica GM, et al. A Dexamethasone Sparing-Regimen with Daratumumab and Lenalidomide in Frail Patients with Newly-Diagnosed Multiple Myeloma: efficacy and Safety Analysis of the Phase 3 IFM2017-03 Trial. Blood. 2022;140:1369\u201370.","journal-title":"Blood"},{"issue":"9","key":"4195_CR49","doi-asserted-by":"publisher","first-page":"680","DOI":"10.1038\/s41571-025-01041-x","volume":"22","author":"MA Dimopoulos","year":"2025","unstructured":"Dimopoulos MA, Terpos E, Boccadoro M, Moreau P, Mateos MV, Zweegman S, et al. EHA\u2013EMN evidence-based guidelines for diagnosis, treatment and follow-up of patients with multiple myeloma. Nat Rev Clin Oncol. 2025;22(9):680\u2013700.","journal-title":"Nat Rev Clin Oncol"},{"issue":"2","key":"4195_CR50","doi-asserted-by":"publisher","first-page":"1","DOI":"10.46989\/001c.133682","volume":"7","author":"W Chen","year":"2025","unstructured":"Chen W, Cai Z, Chim JC, Chng WJ, Du J, Fu C, et al. Consensus Guidelines and Recommendations for The CD38 Monoclonal Antibody-based Quadruplet Therapy and Management in Clinical Practice for Newly Diagnosed Multiple Myeloma: From the Pan-Pacific Multiple Myeloma Working Group. Clin Hematol Int. 2025;7(2):1\u201319.","journal-title":"Clin Hematol Int"},{"issue":"4","key":"4195_CR51","doi-asserted-by":"publisher","first-page":"1066","DOI":"10.1038\/s41375-021-01488-8","volume":"36","author":"T Facon","year":"2022","unstructured":"Facon T, Cook G, Usmani SZ, Hulin C, Kumar S, Plesner T, et al. Daratumumab plus lenalidomide and dexamethasone in transplant-ineligible newly diagnosed multiple myeloma: frailty subgroup analysis of MAIA. Leukemia. 2022;36(4):1066\u201377.","journal-title":"Leukemia"},{"issue":"23","key":"4195_CR52","doi-asserted-by":"publisher","first-page":"5993","DOI":"10.1182\/bloodadvances.2024014139","volume":"8","author":"MS Ebraheem","year":"2024","unstructured":"Ebraheem MS, Chakraborty R, Rochwerg B, Visram A, Mohyuddin GR, Venner CP, et al. Quadruplet regimens for patients with newly diagnosed multiple myeloma: a systematic review and meta-analysis. Blood Adv. 2024;8(23):5993\u20136002.","journal-title":"Blood Adv"},{"issue":"12","key":"4195_CR53","doi-asserted-by":"publisher","first-page":"1943","DOI":"10.3390\/cancers17121943","volume":"17","author":"I Ntanasis-Stathopoulos","year":"2025","unstructured":"Ntanasis-Stathopoulos I, Filippatos C, Malandrakis P, Koutoulidis V, Kastritis E, Terpos E, et al. Upfront Anti-CD38 Monoclonal Antibody-Based Quadruplet Therapy for Multiple Myeloma: A Systematic Review and Meta-Analysis of Clinical Trials. Cancers. 2025;17(12):1943.","journal-title":"Cancers"},{"issue":"1","key":"4195_CR54","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1038\/s41408-025-01253-5","volume":"15","author":"JTD Souto Filho","year":"2025","unstructured":"Souto Filho JTD, Cantadori LO, Crusoe EDQ, Hungria V, Maiolino A. Daratumumab-based quadruplet versus triplet induction regimens in transplant-eligible newly diagnosed multiple myeloma: a systematic review and meta-analysis. Blood Cancer J. 2025;15(1):37.","journal-title":"Blood Cancer J"},{"issue":"1","key":"4195_CR55","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1038\/s41408-025-01413-7","volume":"15","author":"JTD Souto Filho","year":"2025","unstructured":"Souto Filho JTD, Cantadori LO, Crusoe EDQ, Hungria V, Maiolino A. Survival impact of anti-CD38-based quadruplet regimens in transplant-ineligible newly diagnosed multiple myeloma: a network meta-analysis and reconstructed individual patient data meta-analysis. Blood Cancer J. 2025;15(1):212.","journal-title":"Blood Cancer J"},{"key":"4195_CR56","doi-asserted-by":"crossref","unstructured":"Neupane K, Singstock M, Shah D, Dahal R, Mian H, Smith F, et al. Inconsistent definitions of transplant ineligibility in multiple myeloma: a systematic review. Br J Haematol. 2026 Jan 2;bjh.70323.","DOI":"10.1111\/bjh.70323"}],"container-title":["International Journal of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-026-04195-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12185-026-04195-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-026-04195-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T11:03:09Z","timestamp":1782471789000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12185-026-04195-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,2]]},"references-count":56,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["4195"],"URL":"https:\/\/doi.org\/10.1007\/s12185-026-04195-1","relation":{},"ISSN":["0925-5710","1865-3774"],"issn-type":[{"value":"0925-5710","type":"print"},{"value":"1865-3774","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,2]]},"assertion":[{"value":"19 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 March 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 March 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 April 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors have no conflicts of interest to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}